...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma
【24h】

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma

机译：血清细胞因子的谱及其对外周T细胞淋巴瘤患者的临床意义

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To better predict the outcomes of patients with peripheral T-cell lymphoma (PTCL), we measured the levels of various cytokines in serum samples from patients with PTCL and analyzed their clinical outcomes. We measured 34 cytokines in samples from 121 PTCL patients (55 PTCL-not otherwise specified (NOS), 44 angioimmunoblastic T-cell lymphoma (AITL), and 22 ALK(-) anaplastic large cell lymphoma) at diagnosis. Their impact on clinical outcomes, including overall survival and complete response rate, were analyzed with other clinical variables. The median age of patients was 58 years (range, 20-85 years) and 81 patients (66.9%) were male. The median overall survival among all patients was 56.1 months (95% CI 21.4-90.8) and median progression-free survival was 19.3 months (95% CI 12.3-26.3). Patients with AITL were more likely to express higher levels of serum cytokines, and 7 cytokines showed mean levels that were significantly higher than those in other subtypes. In this subgroup, IL-10 higher than 3.8 pg/mL was associated with adverse outcomes. In patients with ALK(-) anaplastic large cell lymphoma, 9 cytokines showed a prognostic impact, with higher levels of interferon gamma, interleukin (IL)-8, IL-10, IL-17, IL-23, IP-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1 beta, and RANTES negatively affecting clinical outcomes. In PTCL-NOS, patients with elevated levels of interferon gamma, IL-7, and IL-23 showed poor outcomes. The current analysis demonstrated different cytokine profiles according to histologic subtype, which revealed the heterogeneity of PTCL. In addition, cytokine levels can be used as prognostic markers and may be useful for therapeutic applications in PTCL patients.
机译：为了更好地预测外周T细胞淋巴瘤（PTCL）的患者的结果，我们测量了PTCL患者的血清样品中各种细胞因子的水平，并分析了它们的临床结果。我们在诊断中测量了来自121个PTCL患者的样品中的34个细胞因子（55 pTCL - 未指定（NOS），44个血管免疫细胞T细胞淋巴瘤（AIT1）和22个ALK（ - ）包塑性大细胞淋巴瘤）。与其他临床变量分析了它们对临床结果的影响，包括整体存活和完全应答率。患者的中位年龄为58岁（范围，20-85岁）和81名患者（66.9％）是男性。所有患者的中位整体生存率为56.1个月（95％CI 21.4-90.8），中位进展生存率为19.3个月（95％CI 12.3-26.3）。含有Ait1的患者更有可能表达较高水平的血清细胞因子，7个细胞因子显示出明显高于其他亚型的细胞因子。在该亚组中，高于3.8 pg / ml的IL-10与不利结果有关。在ALK（ - ）的患者中，9个细胞因子，9个细胞因子显示出预后的影响，具有更高水平的干扰素γ，白细胞介素（IL）-8，IL-10，IL-17，IL-23，IP-10，单核细胞化学毒性蛋白-1，巨噬细胞炎症蛋白-1β，并咆哮对临床结果产生负面影响。在PTCL-NOS中，干扰素γ，IL-7和IL-23升高的患者表现出差的结果。目前的分析根据组织学亚型证明了不同的细胞因子谱，这揭示了PTCL的异质性。此外，细胞因子水平可用作预后标志物，可用于PTCL患者的治疗应用。

著录项

  • 来源
    《Cytokine》 |2019年第2019期|共9页
  • 作者

    Yi Jun Ho; Ryu Kyung Ju; Ko Young Hyeh; Kim Won Seog; Kim Seok Jin;

  • 作者单位

    Chung Ang Univ Div Hematol Oncol Dept Med Seoul South Korea;

    Sungkyunkwan Univ Samsung Adv Inst Hlth Sci &

    Technol Dept Hlth Sci &

    Technol Seoul South Korea;

    Sungkyunkwan Univ Dept Pathol Samsung Med Ctr Sch Med Seoul South Korea;

    Sungkyunkwan Univ Samsung Adv Inst Hlth Sci &

    Technol Dept Hlth Sci &

    Technol Seoul South Korea;

    Sungkyunkwan Univ Samsung Adv Inst Hlth Sci &

    Technol Dept Hlth Sci &

    Technol Seoul South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Peripheral T-cell lymphoma; Serum cytokines; Prognosis;

    机译：外周T细胞淋巴瘤;血清细胞因子;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号